The Gyps-mediated pharmacological effects were abrogated in FXR KO mice, indicating a direct role for FXR in the Gyps-associated reduction of liver inflammation in a murine model of HFD-induced NASH, and that this effect was achieved through FXR activation. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.